1 Five years functional connectivity reorganization without clinical or cognitive decline in MS

- 2
- 3 Einar August Høgestøl^{*, a, b}, Samuele Ghezzo^{*, c, d}, Gro Owren Nygaard^a, Thomas Espeseth^{e, f}, Piotr Sowa^g,
- 4 Mona K. Beyer^{b, g}, Hanne Flinstad Harbo^{a, b}, Lars T. Westlye^{c, e, h}, Hanneke E. Hulst^{d, i}, Dag Alnæs^c
- ^a Oslo University Hospital, Department of Neurology, Oslo, Norway
- 6 ^b University of Oslo, Institute of Clinical Medicine, Oslo, Norway
- 7 ^c NORMENT, Division of Mental Health and Addiction, Oslo, Norway
- 8 ^d Vrije Universiteit Amsterdam, Department of Neuroscience, Amsterdam, The Netherlands
- 9 ^e University of Oslo, Department of Psychology, Oslo, Norway
- 10 ^f Bjørknes College, Oslo, Norway
- ^g Oslo University Hospital, Division of Radiology and Nuclear Medicine, Oslo, Norway
- 12 ^h University of Oslo, KG Jebsen Centre for Neurodevelopmental Disorders, Oslo, Norway
- 13 ⁱ Amsterdam UMC, Amsterdam Neuroscience, Department of Anatomy and Neurosciences, MS Center
- 14 Amsterdam, Amsterdam, The Netherlands
- 15
- 16 * Einar August Høgestøl and Samuele Ghezzo contributed equally to this work as first authors.
- 17
- 18 **Keywords:** multiple sclerosis, functional neuroimaging, fMRI, cohort studies, all
- 19 neuropsychological/behaviour
- 20 Corresponding author:
- 21 Einar August Høgestøl
- 22 Department of Neurology, Neuroscience Research Unit, Multiple Sclerosis Research Group University of
- 23 Oslo & Oslo University Hospital
- 24 Domus Medica 4, room L-268, Gaustadalleén 34
- 25 0372 Oslo, Norway
- 26 E-mail: einar.august@gmail.com
- 27 Mobile: +47 41 10 89 81
- 28
- 29 Characters in title: 93 (Max 96)
- 30 Abstract: 249 (Max 250)
- 31 Introduction: 250 (Max 250)
- 32 Main text: 4269 (Max 4500)
- 33 References: 44 (Max 50)
- 34 Items: 7 (Max 7)

35 ABSTRACT

36	Objective : 1) To assess fMRI-based functional connectivity (FC) anomalies in early multiple sclerosis
37	(MS), 2) To determine the relation between FC changes and structural brain damage due to disease
38	progression 3) To study the association between FC changes and cognitive and physical disability.
39	Methods: Structural MRI and resting-state fMRI were acquired from 76 early relapsing-remitting MS
40	patients at baseline (average disease duration 71.7 months \pm 63) and after five years. Ninety-four
41	healthy controls (HCs) matched for age and sex were included at baseline. Independent component
42	analysis (ICA) and network modelling were used to measure FC. FC variation was related to
43	expanded disability status scale and neuropsychological outcomes. Brain and lesion volumes were
44	quantified using standard methods. We used the 25 independent components obtained from ICA to
45	estimate the longitudinal stability of the brain connectome as a proxy for functional reorganization
46	over time.
47	Results: The MS subjects were clinically and cognitively stable. Compared to HCs, FC abnormalities
48	were detected within networks and in single connections in patients with early MS at baseline. Over
49	time, FC was relatively invariable, but changes in FC were associated with progression of brain
50	atrophy (ρ = 0.39, p = .06). No significant relationship with clinical and cognitive measures or lesion
51	load was detected.
52	Conclusion: Patients with MS showed evidence of altered FC in the early stages of the disease. Over
53	time, changes in FC seem to be related to a progression of brain atrophy, which are known to
54	precede changes in clinical and cognitive functioning.

55 INTRODUCTION

56	Multiple sclerosis (MS) is a disease characterized radiologically by the accumulation of lesions in grey
57	and white matter over time throughout the CNS ^{1, 2} . Brain white matter constitutes the structural
58	connectivity backbone supporting large-scale brain functional network connectivity ^{3, 4} . Accumulating
59	evidence has demonstrated abnormal patterns of brain functional connectivity (FC) in MS patients as
60	compared to healthy controls (HCs) $^{5-12}$. Extensive evidence shows that FC abnormalities are
61	associated with clinical disability in ${\sf MS}^{5,6,8-10,12}$, with a complex pattern of the directionality of FC
62	effects ¹³ . A longitudinal approach that accounts for all alterations in FC following structural damage
63	in MS is warranted to better understand the complex interplay between disease progression and FC
64	reorganization ¹³ .
65	We investigated a prospectively collected MS cohort with comprehensive imaging and
05	
66	clinical data at two time points over five years. First, we explored the baseline resting-state (rs) fMRI
67	MS-data and compared this to a group of age-matched HCs from the same scanner. Then, we used
68	rs-fMRI data to compute the longitudinal stability of each patients' brain functional connectome ¹⁴ ,
69	reducing the complex dynamics of the functional connectome into a single, individual-level global
70	marker of longitudinal network reorganization. The resulting rs-fMRI global measure of connectome
71	stability was compared to brain atrophy, lesion load and clinical and cognitive outcomes. Our
72	hypotheses were 1) MS affects FC in early stages of disease, 2) disease progression is associated with
73	FC reorganization over a five-year interval and 3) an individual-level global measure of connectome
74	stability is associated with clinical trajectories in MS.
75	METHODS

76 Participants

We included 76 MS patients from a prospective longitudinal study at Oslo University Hospital¹⁵⁻¹⁷. All
patients were diagnosed between January 2009 and October 2012 with relapsing-remitting MS
(RRMS) according to the revised McDonald Criteria¹⁸. One patient originally categorized as RRMS

80	was later re-evaluated to be primary-progressive (PP) MS, although with relapses and MRI activity.
81	The patient was excluded from image analysis due to missing rs-fMRI data. Early MS was defined as
82	within the first 10 years of MS symptoms onset. Six participants were not examined with the rs-fMRI
83	sequence at baseline, resulting in 70 patients eligible for the image analyses. All participants were
84	invited for follow-up, five years after the first time point. At follow-up, 62 patients were assessed,
85	with two patients missing the rs-fMRI sequence. Inclusion criteria included age between 18 and 50
86	years, < 3 years since diagnosis of RRMS at baseline, \geq 6 weeks since the last relapse or corticoid
87	treatment, fluency in Norwegian language, right handedness, no prior neurological or psychiatric
88	disease, no head injury and no substance abuse. We excluded pregnant or breastfeeding patients
89	and a patient with a previous adverse reaction to gadolinium injection.
90	Cross-sectional data from HC (n=94, age- and sex-matched with respect to the patient
91	sample) were sampled from the Norwegian Cognitive NeuroGenetics (NCNG) cohort, recruited
92	through newspaper advertisements in the Oslo area ¹⁹ . Inclusion criteria were age between 20 and
93	80 years, no previous diseases affecting the CNS and no previous or current substance abuse.
94	Neurological assessment
95	All MS patients completed a comprehensive neurological examination at baseline and follow-up,
96	including assessment of the expanded disability status scale (EDSS) within the same week as the MRI
97	scan. Physical ability of MS patients was assessed using the Timed 25-Foot Walk (T25-FW) and the 9-
98	hole peg test. No evidence of disease activity (NEDA) -3 was defined as the absence of clinical
99	relapses, new or enlarging MRI lesions and clinical progression as measured by EDSS. First line
100	treatment included interferons, glatiramer acetate, teriflunomide and dimethyl fumarate, while
101	second line treatment included fingolimod, natalizumab and alemtuzumab.
102	Furthermore, all subjects completed a fatigue self-report questionnaire (FSS) ²⁰ and
103	underwent cognitive evaluation. FSS mean scores of \geq 5 were defined as clinically significant
104	fatigue ²¹ . The cognitive evaluation included tests for processing speed, executive functioning,

visuospatial and verbal memory (see Supplemental). In order to obtain a measure of average
cognition we first calculated Z-scores for each of the tests administered. Then, we averaged Z-scores
within the four cognitive domains previously described, and eventually we averaged the scores
across domains, obtaining a measure of overall cognition for each of the MS patients at both time
points. Similarly, we averaged the Z-scores for T25-FW and 9-hole peg test to obtain a measure of
physical ability.

111 Cross-sectional California Verbal Learning Test-II (CVLT-II) and colour-word interference test 112 (CWIT) data from the NCNG HC sample and summary statistics for the remaining tests obtained from 113 an Amsterdam HC sample²² were used for comparison with the patient group. We considered an 114 annual decline of 0.25 SD in average cognition and physical performance as significant²².

115 MRI acquisition and structural MRI pre- and post-processing

All MS and HC subjects were scanned using the same 1.5 T scanner (Avanto, Siemens Medical

117 Solutions; Erlangen, Germany) equipped with a 12-channel head coil. For rs-fMRI we used a T2*

118 weighted echo-planar imaging (EPI) sequence (repetition time (TR)=3000 milliseconds (ms), echo

time (TE)=70 ms, flip angle (FA)=90°, voxel size=3.44x3.44x4 mm, field-of-view (FOV)=220,

120 descending acquisition, GeneRalized Auto calibrating Partial Acquisition (GRAPPA) acceleration

factor=2), 28 transversally oriented slices, no gap, with a scan time of 7 minutes and 30 seconds. The

122 rs-fMRI at baseline included 150 volumes, while the follow-up rs-fMRI scan yielded 100 volumes. The

123 rs-fMRI scan for the HCs constituted of 300 volumes. For fMRI pre-processing and analyses we

restricted the rs-fMRI data to the first 100 volumes for all participants. Three dummy volumes were

125 collected to avoid T1 saturation effects. Structural MRI data were collected using a 3D T1-weighted

126 Magnetization Prepared Rapid Gradient Echo (MP-RAGE) sequence (TR=2400 ms, TE=3.61 ms, time

- to inversion=1000 ms, FA=8°, matrix 192x192, field of view=240, scan time 7 minutes and 42
- seconds, sagittal slices=160, voxel size =1.20×1.25×1.25 mm). FLAIR sequence parameters were

129 TR=6000 ms, TE=3.33 ms, time to inversion=2200 ms, FOV=260, FA=variable T2, matrix 256 × 204.

Each scan lasted 7 minutes and 2 seconds, sagital slices=176 slices, slice thickness=1 mm, voxel size
1.0x1.0x1.0.

132

133	We performed cortical reconstruction by using the T1-weighted scans and volumetric
134	segmentation with FreeSurfer 5.3 (<u>http://surfer.nmr.mgh.harvard.edu/</u>) ²³ . To extract reliable volume
135	and thickness estimates, images included in the longitudinal MS MRI dataset were processed with
136	the longitudinal stream in FreeSurfer ²⁴ . To further validate the brain volume measure, we studied its
137	association with lesion-filled masks at baseline (see table e-1 in Supplemental data). Lesion volume
138	was based on LesionQuant output ^{25, 26} . To validate the lesion output by LesionQuant we additionally
139	assessed its association with lesion masks previously acquired using Cascade and validated by an
140	experienced neuroradiologist at baseline ²⁷ (see table e-1 in Supplemental data).
141	fMRI pre-processing
142	fMRI was performed using FMRI Expert Analysis Tool (FEAT) Version 6.00, from FMRIB's Software
143	Library (<u>https://fsl.fmrib.ox.ac.uk/</u>) ²⁸ . Head motion was corrected using MCFLIRT ²⁹ before linear
144	trends and low-frequency drifts were removed (high-pass filter of 0.01 Hertz). fMRI images were
145	carefully examined by trained research personnel for image artefacts, such as head motion and
146	missing coverage of the scan window. In total, fMRI scans from ten patients and 13 HCs at baseline
147	and eight patients at follow-up were discarded due to incomplete coverage of the visual and parietal
148	cortex. Scans in which the mean relative motion parameter (defined as the average of the
149	translational motion for each scan relative to the previous scan) exceeded 2.5 SD from the average
150	of all runs (across scans) were discarded (none in our MS sample). Brain extraction tool ³⁰ was used to
151	remove non-brain tissue. Spatial smoothing was performed using a Gaussian kernel filter with a full
152	width at half maximum (FWHM) of 6 mm 31 . FMRIB's Nonlinear Image Registration tool (FNIRT) was
153	used to register the participants fMRI volumes to Montreal Neurological Institute (MNI) 152
154	standard using the T1-weighted scan as an intermediate, which had the non-brain tissue removed

using procedures for automated volumetric segmentation in Freesurfer 5.3

156 (<u>http://surfer.nmr.mgh.harvard.edu/</u>)²³.

157	Single-session independent component analysis (ICA) was performed for all runs using
158	Multivariate Exploratory Linear Optimized Decomposition into Independent Components
159	(MELODIC) ³² . We used FIX ³³ for automatic classification of the single-session ICA into signal and noise
160	components, in order to regress noise components from fMRI data. Data cleaning also included
161	correction based on the estimated motion parameters for each run, using linear regression. These
162	ICA-based procedures for denoising of fMRI-data efficiently reduce motion induced variability,
163	outperforming methods based on regression of motion parameters, scrubbing or de-spiking ³⁴ .
164	ICA and functional connectivity matrices
165	The cleaned and MNI-conformed rs-fMRI datasets were submitted to temporal concatenation group

independent component analysis (gICA) using MELODIC³² with a model order of 40. These group 166 167 level spatial components were then used as spatial repressors against the original rs-fMRI datasets to estimate subject-specific components and associated time series (dual regression)³⁵. After 168 169 removing 15 ICs that originated in non-CNS areas and therefore were classified as noise components 170 by a careful evaluation, we extracted a total of 25 ICs for further analysis. The times series of the 171 noise-ICs were regressed out of the time series of the kept ICs. We then calculated connectivity 172 matrices using full as well as regularized partial correlations with automatic estimation of regularization parameters at the individual level^{36, 37}. Based on the Euclidean distances of the full 173 174 temporal correlations, the ICs grouped into four clusters largely representing (1) and (2) default 175 mode network (DMN) and frontoparietal areas, (3) auditory network and (4) sensory/motor areas 176 (figure 1). For detailed information regarding the specific ICs or the anatomical constitution of the 177 networks, please refer to table e-2 in Supplemental Data. Finally, since partial correlations are 178 assumed to represent direct connections between nodes, these were used in further analyses of 179 case-control differences and connectome stability.



Figure 1 Hierarchical clustering of brain nodes. (A) Dendrogram showing the clustering of the nodes, based on the full correlations across conditions and participants. The colours of the dendrograms represent the four ICA clusters (1), (2), (3) and (4), from left to right. (B) The 25 ICs from group ICA used in the analyses. (C) The full correlation matrix across conditions and participants is shown below the diagonal. Regularized partial correlation across conditions are presented above the diagonal. Warm colours indicate positive correlations, cold colours negative correlations.

187

188 **Connectome stability**

We computed the stability of the brain functional connectome for each MS patient as a proxy for FC reorganization. We vectorized each participant's whole-brain connectivity matrix, creating a vector of size 1 x 300 (25 ICs and 300 unique links between them). Then, we calculated the within subjects Spearman correlation coefficient between fMRI at baseline and follow-up, in this way obtaining a measure of whole-brain connectome stability¹⁴. Similarly, we computed the within-network connectome stability for each of the four clusters previously identified. Alterations in the rank of edges across the connectome between baseline and follow-up, independent of their direction, will

- 196 be reflected in the connectome stability, providing an individual global and network-specific
- 197 measure of FC reorganization for the MS patients. To further validate the implementation of the
- 198 stability of the brain functional connectome as a measure that accounts for all changes in FC over
- 199 time, we correlated connectome stability with the sum of the squared differences in FC between
- 200 baseline and FU for all edges in each of the MS patients.

201 Statistical analysis

- 202 For statistical analyses, we used R³⁸ and MATLAB version 2014a (The MathWorks Inc., Natick, MA,
- 203 2018). The changes in performance for all cognitive and clinical tests between baseline and follow-
- 204 up were measured by paired sample t-tests.
- 205 We used separate multivariate linear models to test for differences in whole brain FC, within
- 206 network FC, and FC at the level of single edges between HCs and MS patients at baseline. We
- 207 performed paired sample t-tests to assess changes in FC over time in the MS cohort.
- 208 To investigate whether disease progression was associated with functional reorganization,
- 209 we used separate multivariate linear models to compare whole brain, and within network,
- 210 connectome stability between patients that showed evidence of disease activity (EDA) and patients

211 with NEDA. To further test the hypothesis that structural damage due to disease progression is

- associated with a reduction in the stability of the functional connectome we correlated whole brain
- 213 functional connectome stability of EDA patients with measures of brain volume loss and
- accumulation of lesion load over five years. For lesion volumes we used log transformation, plus a
- constant k = 2, to account for the lack of normal distribution in the resulting volumes.
- Finally, we used multivariate linear models to assess the relationship between connectome stability with cognition and physical ability at follow-up, and on the change in these tests between baseline and follow-up.
- 219 We adjusted for sex, age, mean relative motion and signal to noise ratio in all linear models. 220 Significance was defined as p < .05 in all the performed tests. In the first part of the study, when we

221	compared FC between	n HCs and MS patients and	later investigated cha	anges in FC over time in the MS
-----	---------------------	---------------------------	------------------------	---------------------------------

- 222 cohort, we corrected p value for multiple testing by false discovery rate. Due to the limited sample
- size of the subgroups, we used permutation testing to correct p value for multiple testing in the
- comparisons of connectome stability between EDA and NEDA patients. Specifically, we obtained an
- 225 empirical null-distribution of estimates for the group difference across 1000 permutations randomly
- 226 permuting the group-label. The family wise error was controlled by collecting the maximum test
- statistic across the whole brain and within-network tests for each permutation³⁹. The resulting p
- value was calculated by dividing the number of permuted beta-values equal or larger than the point
- 229 estimate by the total number of permutations.

230 Standard protocols approval, registrations, and patient consents

- 231 The project was approved by the regional ethical committee of South Eastern Norway (REC ID:
- 232 2011/1846, 2016/102 and 2009/2070), and all participants received oral and written information
- and gave their written informed consent.

234 Data availability

- Summary data as published in this paper will be available, but other data are not publicly available
- because of patient privacy restrictions decided by the Regional Ethical Committee. We may apply for
- 237 permission to share data with new collaborators, still adhering to patient privacy requirements of
- the "Law of Health Research". All code needed to replicate our described analyses is available upon
- request from the corresponding author.

240 **RESULTS**

241 Sample characteristics at baseline and follow-up

- Our MS sample included 71% (N=54) females, in line with the prevalence of MS in the general
- population. At follow-up 44% (N=27) of the patients met criteria for NEDA-3. The median EDSS (2.0)
- score did not change after five years. Only one patient developed secondary progressive MS (SPMS)
- at follow-up. Mean time between baseline and follow-up was 4.5 years (SD = 0.4 years, range = 3.7-

- 246 5.4 years). Disease modifying treatment (DMT) were used by 78% and 69% of the patients at
- 247 baseline and follow-up, respectively (table 1). The proportion of patients using second line
- treatment increased from 13% at baseline to 32% at follow-up. HCs were matched to the MS sample
- at baseline by age (HC mean years = 34.89, SD = 9.17) and sex (74% of HC were female). 70% of HCs
- 250 from the Amsterdam sample were females, (mean age years = 41.86, SD = 11.44).

Table 1 Demographic and clinical characteristics of the multiple sclerosis patients

	Baseline	Follow-up
(a) Demographic characteristics	n=76	n= 62
Female, n (%)	54 (71)	44 (71)
Age, mean years (SD)	35.3 (7.3)	40.5 (7.2)
Disease duration, mean months (SD)	71.7 (63)	125.1 (60.2)
Age at first symptom, mean years (SD)	29.3 (6.7)	
Months since diagnosis, mean (SD)	14.0 (11.9)	66.4 (14.5)
Disease modifying treatment		
None, n (%)	17 (22)	19 (31)
First line treatment, n (%)	49 (65)	23 (37)
Second line treatment, n (%)	10 (13)	20 (32)
(b) Clinical evaluation		
Multiple sclerosis classification		
RRMS, n (%)	75 (99)	60 (96)
PPMS, n (%)	1 (1)	1 (2)
SPMS, n (%)		1 (2)
Neurological disability		
EDSS, median (SD, range)	2.0 (0.9, 0-6)	2.0 (1.3, 0-6)
MSSS (SD)	4.9 (1.9)	2.6 (1.8)
Number of total relapses, mean (SD)	1.8 (1)	2.6 (1.3)

FSS, mean (SD)	4.2 (1.7)	4.13 (1.9)
(c) NEDA assessment		
NEDA-3, n (%)		27 (44)

OCB, oligoclonal bands; RRMS, relapsing-remitting multiple sclerosis; PPMS, primary-progressive multiple sclerosis; SPMS, secondary-progressive multiple

sclerosis; EDSS, expanded disability status scale; MSSS, multiple sclerosis severity scale; FSS, fatigue severity scale; NEDA, no evidence of disease activity.

- 251
- The performance of MS patients on all cognitive tests of the CWIT, in addition to the CVLT-II, improved over time (table e-3 in Supplemental Data). The performance in symbol digit modalities test, that also was used to investigate processing speed, did not change over time (table e-3 in

255 Supplemental Data). Both T25-FT and 9-hole peg test at follow-up did not show any significant

development when compared to baseline (table e-3 in Supplemental Data).

- 257 We found no effects of motion parameters such as signal to noise ratio and mean relative
- 258 motion with clinical and cognitive outcomes (table e-4 in Supplemental Data).

259 Functional connectivity abnormalities in MS versus HCs at baseline

260 Overall FC, for the complete combined functional connectome, was lower in MS patients compared

to HCs. FC within three of the four large-scale networks investigated was significantly decreased in

- 262 MS patients. After correction for multiple testing only network 1 and 2 remained significantly
- 263 different from controls (table 2). Edge wise analysis showed that a connection (IC11-IC15) in network
- 1 was weaker in MS relative to controls (β = 0.1, t(135)= -5.21, p = .0002), while another (IC6-IC11)
- one was stronger in patients compared to HCs (β = 0.07, t(135)= 3.54, p = .032). An edge (IC10-IC14)
- 266 in network 2 was increased in MS (β = 0.08, t(135)= 3.74, p = .002) and within network 3 one
- 267 connection (IC7-IC16) decreased intensity in patients relative to controls (β = 0.08, t(135) = 3.94, p
- 268 = .001). Also, a connection (IC2-IC7) between networks 3 and 4 was altered in MS patients (β = -
- 269 0.08, t(135)= 4.02, p = .001). Figure 2 lists the comparisons in FC between MS and HCs at the level

- 270 of single connections, showing that FC abnormalities are bidirectional in MS (figure e-1 in
- 271 Supplemental data for complete p values).
- 272 FC did not change significantly over time in the MS cohort, as measured by paired sample t-
- test between all ICs considered singularly, and between ICs grouped into networks, across time
- 274 (figure e-2, e-3 and table e-5 in Supplemental Data). Additional analysis including careful lesion
- 275 masking during the estimation of the node time series did not change the main effects or
- 276 interpretation of the results (figure e-4 in Supplemental Data).
- 277

Table 2 Within network functional connectivity abnormalities in MS

	Beta coefficient	T value	Standard deviation	P value
Full brain	-0.001	-1.28	0.001	0.2
Network 1	-0.017	-3.56	0.005	0.002 *
DMN and frontoparietal nodes				
Network 2	-0.011	-3.14	0.003	0.004 *
DMN and frontoparietal nodes				
Network 3	-0.009	-1.59	0.006	0.15
Auditory nodes				
Network 4	0.002	0.41	0.005	0.68
Sensory and motor nodes				

Results of multivariate linear regression models corrected for sex, age, mean relative motion and signal to noise ratio. P values corrected for multiple testing

by false discovery rate. * P value significant after correction for multiple testing by false discovery rate



278

279 Figure 2 Edgewise analysis of functional connectivity abnormalities in MS vs HCs. T values form

280 multivariate linear regressions assessing differences in FC at the level of single connections between

281 MS and HCs. Warm colours indicate increased FC in MS, cold colours a decrease in FC. * P value

significant after correction for multiple testing by false discovery rate.

283

284 **Connectome stability over time**

- 285 The stability of the brain functional connectome in the whole MS cohort, and in the EDA and NEDA
- subgroups are depicted in Figure 3, enabling visualization of FC reorganization. Connectome stability
- of network 2 was lower in EDA patients compared to NEDA patients ($\beta = 0.14$, t(34) = 2.26, p = .03),
- but did not survive correction for multiple testing (table e-6 in Supplemental Data).



289

Figure 3 Stability of the brain functional connectome between baseline and follow-up for the MS sample as a whole, and for the subgroups of EDA and NEDA, respectively for the global estimate and all resulting networks. We found a trend were the patients in the EDA subgroup compared to both patients with NEDA and HC patients had improved connectome stability.

294







Figure 4 Correlation between structural damage and stability of the brain functional connectome.

307 (A) correlation between brain atrophy and the rate of FC reorganization, $\rho = 0.40$, p = .06. (B)

308 correlation between accumulation of lesion volume over time and the rate of FC reorganization, $\rho =$

309 0.13, p = .63.

310

311 Clinical relevance of functional connectivity changes

Finally, we explored the effects of the changes in FC on cognitive performance and physical ability using separate general linear models with average cognition and physical ability at FU as dependent variables, covarying for age, sex, signal to noise ratio and mean relative motion. Younger age at FU $(\beta = -0.03, t(34) = -2.08, p = .045)$ was associated with better cognitive performance at FU (figure 5A). Neither stability of the brain functional connectome, age, sex, signal to noise ratio nor mean relative

motion were associated with longitudinal changes in cognitive performance (p > .05) (figure 5B).

304

- 318 For physical ability, lower connectome stability ($\beta = 4.56$, t(34) = 2.00, p = .05), higher age at
- 319 FU (β = -0.05, t(34) = -2.45, p = .02) and sex, with women scoring better than men, (β = 0.70, t(34) =
- 320 2.46, p = .02) were associated with decreased physical ability at FU (figure 5C). None of the
- 321 investigated variables were associated with changes in physical performance over time (p> .05)
- 322 (figure 5D).



Figure 5 Effect of FC reorganization on cognitive performance and physical ability. (A) Effect of FC reorganization on average cognition at follow-up, $\beta = 1.98$, t(34) = 1.20, p = .27. (B) Effect of FC reorganization on average change in cognition, $\beta = 1.00$, t(33) = 0.64, p = .52. (C) Effect of FC reorganization on physical ability at follow-up, $\beta = 4.56$, t(34) = 2.00, p = .05. (D) Effect of FC reorganization on average change in physical ability, $\beta = 0.89$, t(33) = 0.33, p = .75.

329

330 DISCUSSION

In this study, we investigated clinical relevance of connectome stability as an individual-level global
marker of longitudinal FC changes, in a five years longitudinal prospective study of patients recently
diagnosed with MS. In addition, we performed a cross-sectional case-control comparison with a
matched group of healthy controls, assessing network- and edgewise FC differences between MS
patients and controls.

The case-control comparison replicated previous reports of bi-directional FC differences in MS compared to a matched HC sample^{11, 40}, supporting our first hypothesis that FC aberrations are present already in the early stages of MS.

339 Schoonheim et al. (2010) have proposed a model for functional reorganization of the brain in relation to structural damage and clinical impairment in MS⁴¹, postulating that, at least in the early 340 341 stages of MS, functional connectivity would increase as a mechanism to suspend the effects of 342 microstructural damage occurring in the brain as a compensatory mechanism to delay clinical 343 disability. Since then, accumulating evidence has established that FC aberrations are in fact 344 bidirectional in MS¹¹, and the authors recognized the first model postulated was overly simplified¹³. 345 Although their intuition and conceptualization of the model for FC reorganization following disease 346 progression in MS was valid, we hypothesize that their measure for FC reorganization was 347 incomplete.

In this study, we present a novel approach enabling us to study individual longitudinal FC reorganization in relation to disease progression in MS. Investigating the longitudinal stability of the brain functional connectome allows us to study the complex dynamics of FC reorganization in MS, finally enabling us to test the model presented by Schoonheim et al.⁴¹, considering not only the increase in FC, but the whole complex interplay of FC changes following structural damage in MS. In accordance with our hypothesis that disease progression in MS was associated with FC

In accordance with our hypothesis that disease progression in MS was associated with FC reorganization as measured by connectome stability, we found that FC changed at a higher rate as brain atrophy, but not lesion volume, increased. In line with the same hypothesis, we expected to

356 see increased FC reorganization in patients experiencing disease activity between baseline and 357 follow-up. Connectome stability in network (2) was lower in EDA patients compared to NEDA 358 patients, however the observed difference between these two sub-groups did not remain significant 359 after correcting for multiple testing. 360 Finally, we assessed the clinical relevance of the connectome stability measure in our 361 sample. We did not observe significant associations between connectome stability and progression 362 of cognitive and physical impairment. A possible reason might be that our MS cohort was 363 remarkably stable in the follow-up period, exemplified by observations that only two participants 364 displayed a significant decrease (defined as an annual reduction of > 0.25 SD in the five years follow-365 up period) in physical ability, and none in average cognition (figure e-5 and e-6 in Supplemental data 366 respectively). Lower connectome stability was associated with lower physical ability at follow-up, but 367 the result was likely to be driven by two outliers performing very poorly at follow-up. We did not 368 detect any association between FC reorganization and average cognition at follow-up. According to the model presented by Schoonheim et al⁴¹, FC reorganization delays the onset of clinical 369 370 impairment. Since we did not detect any worsening in the clinical performance of our MS patients 371 during the observed period of time, it is tempting to speculate whether the FC changes, that 372 occurred, delayed the onset of impairment. Therefore, it will be important to repeat these analyses 373 in a planned follow-up of the group of patients in a few years. 374 Using connectome stability as an individual-level longitudinal measure, by incorporating the 375 global dynamics of FC changes in the brain, has previously been used to study mental health in

adolescent neurodevelopment⁴² as well as severe mental disorders¹⁴, but has so far remained
unexplored in MS. The measure is based on longitudinal within-subjects Spearman correlation
coefficients^{14, 42}. Any change in FC that occurs over time, independent of the direction, will cause a
shift in ranks that lowers the Spearman correlation coefficient, thus providing a global measure
sensitive to relative FC reorganization. However, the shift in ranks of one connection causes the

381 following shift in ranks of all the others, potentially inflating the measure of connectome stability. 382 We correlated the index of connectome stability with the sum of the squared differences in FC to 383 control for possible artefacts due to the implementation of a rank-based measure. Since the 384 correlation is strong, highly significant and goes in the expected direction we are confident that 385 connectome stability is a valid approach to investigate FC reorganization in MS. 386 Our study is, to our knowledge, one of very few published studies investigating longitudinal FC in MS^{40, 43}. In general, our results reproduced and confirmed the results reported by Rocca et al 387 388 and Koubiyr et al. (2019) investigating clinically isolated syndrome (CIS) patients in a longitudinal setting^{40, 43}. All these studies show FC abnormalities at the early phases of the disease and, in line 389 390 with Rocca et al. we found that FC alterations do not correlate with lesion volume. Furthermore,

even though the main approach to study FC reorganization is different in these studies, all data-sets
 suggest brain reorganization during disease progression.

393 A limitation of our study is that we could not investigate the difference in connectome 394 stability between HCs and MS patients due to the lack of MRI at follow-up for HCs. Since HCs 395 performed cognitive tests only at baseline, we used the results of HCs at baseline to create the Z-396 scores for MS patients at follow-up. Z-scores for physical ability were based on analyses of 397 performance of MS patients only. Practice effects in cognitive tests seem to have occurred, but we 398 could not account for them, for example calculating the reliable change index as done by Eijlers et 399 al.²². The sample size of our MS cohort is comparable with that of previous studies investigating FC longitudinally⁴⁰. In sub-group analyses the sample sizes are modest. Finally, functional connections 400 401 of the brain are known to be dynamic, and future studies with longer scan duration may be able to 402 pursue approaches for assessing the dynamic aspects of the FC in the brains of patients with MS.

To conclude, in this longitudinal study we found that our MS cohort was remarkably clinically stable. Only two patients showed a significant decrease in physical ability and cognitive performance was preserved in all participants in the follow-up period. We found that FC abnormalities are

406	bidirectional and occur already at the early stages of MS. We used the stability of the brain
407	functional connectome as a proxy for FC reorganization, enabling us to study FC changes in relation
408	to disease progression. We found that FC reorganization and brain atrophy advance in parallel. In
409	future studies, the MS cohort needs to be followed up again to enable further analyses of functional
410	brain changes and clinical course. Connectome stability enables fMRI data to be condensed into a
411	proxy as an individual marker of brain health in a personalized medical approach to complement the
412	existing biomarkers in MS ⁴⁴ .

413

414 Acknowledgement

415 We thank all patients participating in our studies. We acknowledge the collaboration with members

of the Multiple Sclerosis Research Group and NORMENT at the University of Oslo and Oslo University

417 hospital, especially Elisabeth G. Celius for her guidance during the investigations of the MS patients

418 and Tobias Kaufmann for valuable help and input on the statistical approach. We also thank the

419 research assistants Kristin Liltved Grønsberg, May-Britt Gjengstø Utheim, Julia Timofeeva, Hedda

- 420 Maurud, Siren Tønnessen and Petter Espeseth Emhjellen who all contributed in the cognitive testing
- 421 of the patients.

422

423 Study funding

- 424 The project was supported by grants from the South-Eastern Health Authorities of Norway (grant
- number 2011059/ES563338/Biotek 2021) and by the European Union under the Horizon 2020
 programme (grant number 733161).

427

428 Disclosures

429	E. A. Høgestøl has received honoraria for lecturing from Biogen, Merck and Sanofi-Genzyme, and
430	unrestricted research support from Merck and Sanofi-Genzyme. P. Sowa has received honoraria for
431	lecturing and travel support from Merck. M. K. Beyer has received honoraria for lecturing from
432	Novartis and Biogen Idec. H.F Harbo has received travel support, honoraria for advice or lecturing
433	from Biogen Idec, Sanofi-Genzyme, Merck, Novartis, Roche, and Teva and an unrestricted research
434	grant from Novartis. Hanneke Hulst received honoraria for speaking at scientific meetings, serving at
435	scientific advisory boards and consulting activities from Biogen, Celgene, Genzyme, Merck and
436	Roche. She has received research support from the Dutch MS Research foundation and serves on the
437	editorial board of Multiple Sclerosis Journal (MSJ). S. Ghezzo, G.O. Nygaard, T. Espeseth, L.T. Westlye
438	and D. Alnæs report no disclosures.

- 439 Appendix
- 440 Authors

Name	Location	Contribution
Einar A. Høgestøl, MD	Oslo University Hospital & University of Oslo	Conceived the study, data collection conception and design of the work, data analysis and interpretation, drafting the article, final approval of the version to be published
Samuele Ghezzo, BSc	Oslo University Hospital & University of Oslo	Data analysis and interpretation, drafting the article, final approval of the version to be published
Gro O. Nygaard, PhD	Oslo University Hospital	Conceived the study, data collection conception and design of the work, final approval of the version to be published
Thomas Espeseth, PhD	University of Oslo & Bjørknes College	Data collection, final approval of the version to be published
Piotr Sowa, MD, PhD	Oslo University Hospital	Data collection, final approval of the version to be published
Mona K. Beyer, PhD	Oslo University Hospital & University of Oslo	Data collection and design of the work, final approval of the version to be published
Hanne F. Harbo, PhD	Oslo University Hospital & University of Oslo	Conceived the study, data collection, conception and design of the work, final approval of the version to be published
Lars T. Westlye, PhD	Oslo University Hospital & University of Oslo	Data analysis and interpretation, final approval of the version to be

		published
Hanneke E. Hulst, PhD	Amsterdam UMC & Vrije	Data analysis and interpretation,
	Universiteit Amsterdam	drafting the article, final approval
		of the version to be published
Dag Alnæs, PhD	Oslo University Hospital &	Data analysis and interpretation,
	University of Oslo	drafting the article, final approval
		of the version to be published

441

442 **REFERENCES**

443 1. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Current opinion in 444 neurology 2002;15:239-245. 445 2. Chard D, Trip SA. Resolving the clinico-radiological paradox in multiple sclerosis. F1000Res 446 2017:6:1828. 447 3. Peer M, Nitzan M, Bick AS, Levin N, Arzy S. Evidence for Functional Networks within the 448 Human Brain's White Matter. J Neurosci 2017;37:6394-6407. 449 Smith SM, Fox PT, Miller KL, et al. Correspondence of the brain's functional architecture 4. 450 during activation and rest. Proceedings of the National Academy of Sciences of the United States of 451 America 2009;106:13040-13045. 452 Basile B, Castelli M, Monteleone F, et al. Functional connectivity changes within specific 5. 453 networks parallel the clinical evolution of multiple sclerosis. Multiple sclerosis (Houndmills, 454 Basingstoke, England) 2014;20:1050-1057. 455 Rocca MA, Valsasina P, Martinelli V, et al. Large-scale neuronal network dysfunction in 6. 456 relapsing-remitting multiple sclerosis. Neurology 2012;79:1449-1457. 457 d'Ambrosio A, Valsasina P, Gallo A, et al. Reduced dynamics of functional connectivity and 7. 458 cognitive impairment in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 459 2019:1352458519837707. 460 8. Rocca MA, Valsasina P, Leavitt VM, et al. Functional network connectivity abnormalities in 461 multiple sclerosis: Correlations with disability and cognitive impairment. Multiple sclerosis 462 (Houndmills, Basingstoke, England) 2018;24:459-471. 463 9. Hawellek DJ, Hipp JF, Lewis CM, Corbetta M, Engel AK. Increased functional connectivity 464 indicates the severity of cognitive impairment in multiple sclerosis. Proceedings of the National 465 Academy of Sciences of the United States of America 2011;108:19066-19071. 466 10. Rocca MA, Valsasina P, Absinta M, et al. Default-mode network dysfunction and cognitive 467 impairment in progressive MS. Neurology 2010;74:1252-1259. 468 11. Tahedl M, Levine SM, Greenlee MW, Weissert R, Schwarzbach JV. Functional Connectivity in 469 Multiple Sclerosis: Recent Findings and Future Directions. Frontiers in neurology 2018;9:828. 470 Faivre A, Rico A, Zaaraoui W, et al. Assessing brain connectivity at rest is clinically relevant in 12. 471 early multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18:1251-1258. 472 Schoonheim MM, Meijer KA, Geurts JJ. Network collapse and cognitive impairment in 13. 473 multiple sclerosis. Frontiers in neurology 2015;6:82. 474 14. Kaufmann T, Alnaes D, Brandt CL, et al. Stability of the Brain Functional Connectome 475 Fingerprint in Individuals With Schizophrenia. JAMA psychiatry 2018;75:749-751. 476 15. Nygaard GO, Walhovd KB, Sowa P, et al. Cortical thickness and surface area relate to specific 477 symptoms in early relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, 478 England) 2015;21:402-414. 479 16. Nygaard GO, Celius EG, de Rodez Benavent SA, et al. A Longitudinal Study of Disability, 480 Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of 481 Disease Activity. PloS one 2015;10:e0135974.

482 17. Høgestøl EA, Kaufmann T, Nygaard GO, et al. Cross-Sectional and Longitudinal MRI Brain 483 Scans Reveal Accelerated Brain Aging in Multiple Sclerosis. Frontiers in neurology 2019;10. 484 18. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 485 revisions to the McDonald criteria. Annals of neurology 2011;69:292-302. 486 19. Espeseth T, Christoforou A, Lundervold AJ, Steen VM, Le Hellard S, Reinvang I. Imaging and 487 cognitive genetics: the Norwegian Cognitive NeuroGenetics sample. Twin Res Hum Genet 488 2012;15:442-452. 489 20. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to 490 patients with multiple sclerosis and systemic lupus erythematosus. Archives of neurology 491 1989;46:1121-1123. 492 21. Penner IK, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. Nature 493 reviews Neurology 2017. 494 Eijlers AJC, van Geest Q, Dekker I, et al. Predicting cognitive decline in multiple sclerosis: a 5-22. 495 year follow-up study. Brain : a journal of neurology 2018;141:2605-2618. 496 23. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface 497 reconstruction. NeuroImage 1999;9:179-194. 498 24. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for 499 unbiased longitudinal image analysis. NeuroImage 2012;61:1402-1418. 500 Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical 25. 501 practice. Behav Neurol 2009;21:21-28. 502 W. Luo KL, A. M. Ulug, J. Albright, S. Magda, R. Haxton, C. Airriess. LesionQuant Performance 26. 503 Evaluation 504 Accuracy and Reproducibility (white paper): Cortechs Labs, 2017. 505 Damangir S, Manzouri A, Oppedal K, et al. Multispectral MRI segmentation of age related 27. 506 white matter changes using a cascade of support vector machines. Journal of the neurological 507 sciences 2012;322:211-216. 508 28. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image 509 analysis and implementation as FSL. NeuroImage 2004;23 Suppl 1:S208-219. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and 510 29. 511 accurate linear registration and motion correction of brain images. NeuroImage 2002;17:825-841. 512 30. Smith SM. Fast robust automated brain extraction. Human brain mapping 2002;17:143-155. 513 31. Smith SM, Brady JM. SUSAN—A New Approach to Low Level Image Processing. International 514 Journal of Computer Vision 1997;23:45-78. 515 32. Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity 516 using independent component analysis. Philosophical transactions of the Royal Society of London 517 Series B, Biological sciences 2005;360:1001-1013. 518 Griffanti L, Salimi-Khorshidi G, Beckmann CF, et al. ICA-based artefact removal and 33. 519 accelerated fMRI acquisition for improved resting state network imaging. NeuroImage 2014;95:232-520 247. 521 Pruim RH, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-AROMA: A robust 34. 522 ICA-based strategy for removing motion artifacts from fMRI data. NeuroImage 2015;112:267-277. 523 Nickerson LD, Smith SM, Ongur D, Beckmann CF. Using Dual Regression to Investigate 35. 524 Network Shape and Amplitude in Functional Connectivity Analyses. Front Neurosci 2017;11:115. 525 36. Ledoit O, Wolf M. Improved estimation of the covariance matrix of stock returns with an 526 application to portfolio selection. Journal of Empirical Finance 2003;10:603-621. 527 37. Brier MR, Mitra A, McCarthy JE, Ances BM, Snyder AZ. Partial covariance based functional 528 connectivity computation using Ledoit-Wolf covariance regularization. NeuroImage 2015;121:29-38. 529 R: A Language and Environment for Statistical Computing [computer program]. Vienna, 38. 530 Austria: R Foundation for Statistical Computing, 2017. 531 Singh KD, Barnes GR, Hillebrand A. Group imaging of task-related changes in cortical 39. 532 synchronisation using nonparametric permutation testing. NeuroImage 2003;19:1589-1601.

- 40. Rocca MA, Hidalgo de La Cruz M, Valsasina P, et al. Two-year dynamic functional network
 connectivity in clinically isolated syndrome. Multiple sclerosis (Houndmills, Basingstoke, England)
 2019:1352458519837704.
- 536 41. Schoonheim MM, Geurts JJ, Barkhof F. The limits of functional reorganization in multiple 537 sclerosis. Neurology 2010;74:1246-1247.
- 538 42. Kaufmann T, Alnaes D, Doan NT, Brandt CL, Andreassen OA, Westlye LT. Delayed
- stabilization and individualization in connectome development are related to psychiatric disorders.
 Nature neuroscience 2017.
- 541 43. Koubiyr I, Besson P, Deloire M, et al. Dynamic modular-level alterations of structural-
- functional coupling in clinically isolated syndrome. Brain : a journal of neurology 2019;142:3428-3439.
- 544 44. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple
- sclerosis. Multiple sclerosis and related disorders 2016;9 Suppl 1:S5-S48.

546